Decoy receptor

Last updated on: 20.11.2023

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

A decoy receptor (translatable as "dummy receptor; decoy receptor") is a specific receptor that binds its ligand with high affinity but does not transmit signals.

Due to the binding of ligands to Decoy receptors, fewer ligands are available to the functional receptors, which means that they can only be activated to a lesser extent. As a result, Decoy receptors act as competitive inhibitors of their respective functional counterparts.

General informationThis section has been translated automatically.

Examples of Decoy receptors:

  • Interleukin-1 receptor type 2: IL1R2 was one of the first Decoy receptors identified. It binds IL1a and IL1b and inhibits their binding to the IL1R1 receptor, thereby preventing the inflammatory response that is generally promoted by the binding of type 1 interleukins to the type I interleukin receptor 1.
  • Decoy receptor 3 (DcR3): The DcR3 receptor, also known as TNFRSF6, is found primarily in tumor tissue and acts as a decoy receptor for the TNF cytokines: FasL, LIGHT and TL1A. It inhibits the apoptotic abilities of these cytokines.
  • VEGFR-1: VEGFR-1 is a non-functional kinase-defective receptor tyrosine kinase that negatively modulates angiogenesis by acting as a Decoy receptor. The Decoy property of VEGFR-1 is required for normal development and angiogenesis.
  • Osteoprotegerin: Osteoprotegerin binds RANKL and inhibits the NF-κB signaling pathway and thus the immune response.

Last updated on: 20.11.2023